Interim results were in line with 23 October trading update; sales rising 4% to £7.1m or 1% at constant exchange rates (CER). This resulted in adjusted EBITDA and pre-tax profit of £0.6m (-16%) and £0.2m (-61%), respectively. Despite the significant development progress made over the past year – CE marked Visitect CD4, malaria, and a range of allergens for Allersys (41 with 8 pending) – short-term headwinds in both Food and Allergy have led us to downgrade revenu
14 Dec 2017
Short-term headwinds
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Short-term headwinds
Cambridge Nutritional Sciences PLC (CNSL:LON) | 3.2 0 0.0% | Mkt Cap: 7.73m
- Published:
14 Dec 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
Interim results were in line with 23 October trading update; sales rising 4% to £7.1m or 1% at constant exchange rates (CER). This resulted in adjusted EBITDA and pre-tax profit of £0.6m (-16%) and £0.2m (-61%), respectively. Despite the significant development progress made over the past year – CE marked Visitect CD4, malaria, and a range of allergens for Allersys (41 with 8 pending) – short-term headwinds in both Food and Allergy have led us to downgrade revenu